Albireo Pharma, Inc.
ALBO · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $9,832 | $8,206 | $6,832 | $32,521 |
| % Growth | 19.8% | 20.1% | -79% | – |
| Cost of Goods Sold | $612 | $776 | $234 | $925 |
| Gross Profit | $9,220 | $7,430 | $6,598 | $31,596 |
| % Margin | 93.8% | 90.5% | 96.6% | 97.2% |
| R&D Expenses | $23,312 | $22,888 | $21,903 | $20,602 |
| G&A Expenses | $0 | $0 | $0 | $32,213 |
| SG&A Expenses | $20,564 | $21,600 | $16,855 | $19,744 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $145 | $7,398 | $2,744 |
| Operating Expenses | $43,877 | $44,633 | $46,156 | $43,090 |
| Operating Income | -$34,657 | -$37,203 | -$39,558 | -$11,494 |
| % Margin | -352.5% | -453.4% | -579% | -35.3% |
| Other Income/Exp. Net | -$3,143 | -$2,746 | -$2,876 | -$3,257 |
| Pre-Tax Income | -$37,800 | -$39,949 | -$42,434 | -$14,751 |
| Tax Expense | $613 | $2,746 | $2,876 | -$3,789 |
| Net Income | -$38,413 | -$42,695 | -$45,310 | -$10,962 |
| % Margin | -390.7% | -520.3% | -663.2% | -33.7% |
| EPS | -1.95 | -2.18 | -2.34 | -0.57 |
| % Growth | 10.6% | 6.8% | -310.5% | – |
| EPS Diluted | -1.95 | -2.18 | -2.34 | -0.57 |
| Weighted Avg Shares Out | 19,655 | 19,585 | 19,380 | 19,290 |
| Weighted Avg Shares Out Dil | 19,655 | 19,585 | 19,380 | 19,290 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2,530 | $2,746 | $2,876 | $3,257 |
| Depreciation & Amortization | $124 | $84 | $114 | $107 |
| EBITDA | -$35,146 | -$37,119 | -$39,444 | $8,437 |
| % Margin | -357.5% | -452.3% | -577.3% | 25.9% |